Events & Presentations

Add Files Arbutus Biopharma Corporate Overview 1.7 MB	Add Files Arbutus Biopharma Corporate Overview 1.7 MB

Archived Events

Summary Toggle Oct 20,2020 10:00 AM EDT	H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference Listen to webcast
Summary Toggle Oct 05,2020 1:00 PM EDT	Chardan Virtual 4th Annual Genetic Medicines Conference Listen to webcast
Summary Toggle Sep 28 - 30,2020	International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs, Virtual Meeting Supporting Materials Impact of the hepatitis B virus (HBV) capsid inhibitor, AB-506, on the single dose pharmacokinetics (PK) of a combined oral contraceptive (COC) 242 KB Evaluation of relationships between AB-506 related ALT elevations and AB-506 pharmacokinetics (PK), metabolite concentrations and plasma bile acids 1.3 MB
Summary Toggle Sep 15,2020 10:30 AM EDT	H.C. Wainwright 22nd Annual Global Investment Conference Listen to webcast
Summary Toggle Aug 29,2020	EASL 2020 Supporting Materials Hepatitis B Virus Core Protein Variants Observed In a First-In-Human Placebo-Controlled Study of a Capsid Inhibitor 709.6 KB
Summary Toggle Aug 12,2020 3:30 PM EDT	Wedbush PacGrow Healthcare Virtual Conference Listen to webcast
Summary Toggle Aug 07,2020 8:45 AM EDT	Arbutus Biopharma Corporation 2020 Second Quarter Financial Results and Corporate Update Listen to webcast
Summary Toggle Jun 03,2020 1:30 PM EDT	Jefferies Virtual Healthcare Conference Listen to webcast
Summary Toggle May 19,2020 11:40 AM EDT	UBS Virtual Global Healthcare Conference Listen to webcast
Summary Toggle May 18,2020 4:30 PM EDT	AB-729 Clinical Update Listen to webcast Supporting Materials Presentation 593.9 KB
Summary Toggle May 11,2020 8:00 AM EDT	Arbutus Biopharma Corporation 2020 First Quarter Financial Results and Corporate Update Listen to webcast
Summary Toggle Mar 26,2020 4:30 PM EDT	AB-729 Clinical Update Listen to webcast Supporting Materials Presentation 694.9 KB
Summary Toggle Mar 05,2020 8:45 AM EST	Arbutus Biopharma Corporation Fourth Quarter and Year End 2019 Financial Results and Corporate Update Listen to webcast
Summary Toggle Dec 12,2019	HepDART 2019 Supporting Materials Poster: Key findings leading to the discontinuation of a Capsid Inhibitor (CI), AB-506, in Healthy Subjects (HS) and Chronic Hepatitis B (CHB) Subjects 844.4 KB Presentation: Key findings leading to the discontinuation of a Capsid Inhibitor (CI), AB-506, in Healthy Subjects (HS) and Chronic Hepatitis B (CHB) Subjects 992.3 KB
Summary Toggle Nov 11,2019	AASLD 2019 Supporting Materials A Novel HBV Capsid Inhibitor Compound Series Demonstrates Improved Inhibition of HBV WT, T33N and I105T Core Protein Variants and Shows a Unique Binding Mode to Core Protein 9.8 MB Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Inhibitor (CI) AB-506 in Healthy Subjects (HS) and Chronic Hepatitis B (CHB) Subjects 667.8 KB
Summary Toggle Nov 06,2019 8:45 AM EST	Arbutus Biopharma Corporation 2019 Third Quarter Financial Results and Corporate Update Listen to webcast
Summary Toggle Oct 01 - 05,2019	International HBV Meeting 2019 Supporting Materials Cellular RNA Quality Control Functions Regulate Hepatitis B Virus RNA Steady-State Levels 683.5 KB
Summary Toggle Aug 13,2019 10:55 AM EDT	2019 Wedbush PacGrow Healthcare Conference
Summary Toggle Aug 05,2019 8:45 AM EDT	Arbutus Biopharma Corporation 2019 Second Quarter Financial Results and Corporate Update
Summary Toggle Jul 15,2019 4:45 PM EDT	Arbutus Biopharma Corporation Conference Call
Summary Toggle Jun 20,2019 10:00 AM EDT	JMP Securities Life Sciences Conference
Summary Toggle Jun 05,2019 3:00 PM EDT	Jefferies 2019 Healthcare Conference
Summary Toggle May 21,2019 11:00 AM EDT	RBC Capital Markets Healthcare Conference
Summary Toggle May 20,2019 1:00 PM EDT	UBS Global Healthcare Conference
Summary Toggle Mar 11,2019 2:50 PM EDT	Cowen and Company 39th Annual Healthcare Conference
Summary Toggle Mar 07,2019 1:30 PM PST	Arbutus Biopharma Corporation Fourth Quarter and Year End 2018 Financial Results and Corporate Update
Summary Toggle Oct 09,2018 2:45 PM EDT	Chardan 2nd Annual Genetic Medicines Conference
Summary Toggle Oct 03 - 06,2018	International HBV Meeting Supporting Materials Mode of action studies on HBV RNA destabilizer AB-452 1.3 MB
Summary Toggle Sep 25,2018	Antivirals: Targeting HBV and Beyond Supporting Materials View Presentation 2.7 MB
Summary Toggle Sep 04,2018 9:50 AM EDT	B. Riley FBR Healthcare Conference
Summary Toggle Aug 15,2018 2:30 PM EDT	2018 Wedbush PacGrow Healthcare Conference
Summary Toggle Jul 10,2018 4:00 PM EDT	Roivant Pipeline Day Listen to webcast
Summary Toggle Apr 12,2018	EASL 2018 Supporting Materials Durable inhibition of hepatitis B virus replication and antigenemia using subcutaneously administered siRNA agent AB-729 in preclinical models 1.5 MB Preclinical antiviral drug combination studies utilizing novel orally bioavailable agents for chronic hepatitis B infection AB-506 a next generation HBV capsid inhibitor and AB-452 an HBV RNA destabilizer 1.3 MB
Summary Toggle Dec 06,2017 3:00 PM PST	HepDART 2017 Supporting Materials A Next Generation HBV Capsid Inhibitor AB-506 In Vitro and In Vivo Antiviral Characterization (Poster) 10.1 MB A Next Generation HBV Capsid Inhibitor AB-506 In Vitro and In Vivo Antiviral Characterization (Presentation) 9.3 MB Controlling HBsAg as a Key Component of a Combination Strategy to Affect an HBV Cure 5 MB
Summary Toggle Oct 22,2017	AASLD 2017 Supporting Materials HBcrAg, HBV-RNA Declines in A Phase 2a Study Evaluating the Multi-Dose Activity of ARB-1467 in HBeAg-Positive and Negative Viral 1.1 MB Pharmacokinetics and exploratory exposure-response of siRNAs administered monthly as ARB-001467 (ARB-1467) in a Phase 2a study i 468.4 KB Antiviral Characterization of a Next Generation Chemical Series of HBV Capsid Inhibitors In Vitro and In Vivo 9.1 MB Identification and Characterization of AB-452, a Potent Small Molecule HBV RNA Destabilizer In Vitro and In Vivo 1.4 MB In Vivo Study of a LNP siRNA Investigational Agent Applied Sequentially with Immunomodulatory Treatments for Chronic Hepatitis B 1.4 MB Single Dose Safety, Tolerability and Pharmacokinetics of AB-423 in Healthy Volunteers from the ongoing Single and Multiple Ascen 790.3 KB Bi-weekly Dosing of ARB-1467 LNP siRNA in HBeAg Negative, Virally Suppressed Patients with Chronic HBV Infection Leads to Deeper 1.3 MB
Summary Toggle Oct 10,2017	Chardan Inaugural Gene Therapy Conference
Summary Toggle Sep 25,2017	Discovery on Target: Targeting HBV Supporting Materials HBV capsid inhibitor AB-423 exhibits a dual mode of action and displays additivesynergistic effects in in vitro combination stud 2 MB RNA Interference: A New Tool in the Toolbox for Treatment of HBV 3 MB RNAi Based Human Therapy for Chronic Hepatitis B Infection 2.7 MB
Summary Toggle Sep 12,2017 1:00 PM EDT	LNP: Delivering mRNA Therapeutics to the Clinic Supporting Materials View Presentation 5.1 MB

Events & Presentations

Presentations

Upcoming Events

Archived Events

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials

Supporting Materials